6XLI

CRYSTAL STRUCTURE OF ANTI-TAU ANTIBODY PT3 Fab+pT212/pT217-TAU PEPTIDE

Summary for 6XLI

Entry DOI	10.2210/pdb6xli/pdb
Descriptor	PT3 Fab Heavy Chain, PT3 Fab Light Chain, Tau Phosphopeptide (Ac-SR(pT)PSLP(pT)PPTRE-OH), ... (5 entities in total)
Functional Keywords	immunoglobulin fold, antibody, immune system, neuroscience
Biological source	Mus musculus More
Total number of polymer chains	9
Total formula weight	150377.73
Authors	Malia, T.J.,Teplyakov, A.,Luo, J. (deposition date: 2020-06-28, release date: 2020-09-23, Last modification date: 2024-10-30)
Primary citation	Van Kolen, K.,Malia, T.J.,Theunis, C.,Nanjunda, R.,Teplyakov, A.,Ernst, R.,Wu, S.J.,Luo, J.,Borgers, M.,Vandermeeren, M.,Bottelbergs, A.,Wintmolders, C.,Lacy, E.,Maurin, H.,Larsen, P.,Willems, R.,Van De Casteele, T.,Triana-Baltzer, G.,Slemmon, R.,Galpern, W.,Trojanowski, J.Q.,Sun, H.,Mercken, M.H. Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. J Alzheimers Dis, 77:1397-1416, 2020 Cited by PubMed Abstract: As a consequence of the discovery of an extracellular component responsible for the progression of tau pathology, tau immunotherapy is being extensively explored in both preclinical and clinical studies as a disease modifying strategy for the treatment of Alzheimer's disease. PubMed: 32894244 DOI: 10.3233/JAD-200544 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2 Å)

Structure validation